<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Molecular biology of acute promyelocytic leukemia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Molecular biology of acute promyelocytic leukemia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Molecular biology of acute promyelocytic leukemia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Wendy Stock, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael J Thirman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard A Larson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 04, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Acute myeloid leukemia (AML) refers to a group of hematopoietic neoplasms involving cells committed to the myeloid lineage. Acute promyelocytic leukemia (APL) is a biologically and clinically distinct variant of AML. In the World Health Organization classification system, APL is classified as acute promyelocytic leukemia with <em>PML-RARA</em>; it was previously classified as AML-M3 in the older French-American-British (FAB) classification system [<a href="#rid1">1,2</a>]. (See  <a class="medical medical_review" href="/d/html/86098.html" rel="external">"Acute myeloid leukemia: Classification"</a>.)</p><p>The cytogenetic hallmark of APL is a translocation involving <em>RARA</em>, the retinoic acid receptor alpha locus on chromosome 17 [<a href="#rid3">3</a>]. The vast majority of cases of APL contain t(15;17)(q24.1;q21.1). However, several variant translocations involving <em>RARA</em> have been identified, including t(11;17) and t(5;17) [<a href="#rid4">4-6</a>], and distinguishing between these translocations is important because patients with the variant translocation t(11;17) are almost invariably resistant to <a class="drug drug_general" data-topicid="9262" href="/d/drug information/9262.html" rel="external">all-trans retinoic acid</a> (ATRA) [<a href="#rid4">4,5,7</a>]. (See  <a class="medical medical_review" href="/d/html/4527.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults"</a> and  <a class="medical medical_review" href="/d/html/4498.html" rel="external">"Initial treatment of acute promyelocytic leukemia in adults"</a>.)</p><p>The molecular biology of APL will be discussed here. The molecular biology of acute myeloid leukemias other than APL and of ALL is discussed separately. (See  <a class="medical medical_review" href="/d/html/4493.html" rel="external">"Acute myeloid leukemia: Pathogenesis"</a> and  <a class="medical medical_review" href="/d/html/4484.html" rel="external">"Classification, cytogenetics, and molecular genetics of acute lymphoblastic leukemia/lymphoma"</a> and  <a class="medical medical_review" href="/d/html/4502.html" rel="external">"Acute myeloid leukemia: Molecular genetics"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">RETINOIC ACID AND THE RETINOIC ACID RECEPTOR</span><span class="headingEndMark"> — </span>Retinoic acid (RA) is a critical ligand in the differentiation of multiple tissues, mediated through binding to a retinoic acid receptor (RAR). RARs belong to the nuclear steroid/thyroid hormone receptor superfamily. Of the three RAR isoforms, RAR alpha is expressed primarily in hematopoietic cells.</p><p>RAR alpha is a member of a family of retinoid-binding transcription factors (including RXR) that regulate gene expression. RAR alpha contains discrete functional domains, including an amino terminal transcriptional activation domain, and DNA-binding, dimerization, and retinoid-binding domains. RAR alpha heterodimerizes with retinoid X receptor (RXR), and binds to RA-responsive elements to regulate transcription of target genes [<a href="#rid7">7</a>].</p><p>In the absence of RA, heterodimers of RAR alpha/RXR alpha interact with the nuclear corepressor, N-CoR, a ubiquitous nuclear protein that mediates transcriptional repression [<a href="#rid4">4,8</a>]. RA dissociates N-CoR from the RAR alpha/RXR alpha heterodimer, relieving transcriptional repression and presumably activating genes that lead to terminal differentiation of promyelocytes (<a class="graphic graphic_picture graphicRef76618 graphicRef66640" href="/d/graphic/76618.html" rel="external">picture 1A-B</a>) [<a href="#rid8">8,9</a>].</p><p>The capacity of retinoids to induce myeloid differentiation was recognized prior to the identification of the involvement of RAR alpha in acute promyelocytic leukemia (APL). RA had been shown to enhance the growth of normal myeloid progenitors, to induce differentiation of the HL-60 promyelocytic cell line, and to induce terminal differentiation of primary human APL cells cultured in vitro [<a href="#rid10">10-12</a>]. Subsequently, the use of <a class="drug drug_general" data-topicid="9262" href="/d/drug information/9262.html" rel="external">all-trans retinoic acid</a> (ATRA) was found to induce complete remissions in patients with APL. (See  <a class="medical medical_review" href="/d/html/4498.html" rel="external">"Initial treatment of acute promyelocytic leukemia in adults"</a>.)</p><p>Rather than inducing cell death from cytotoxicity, ATRA induces differentiation of the malignant promyelocytic clone, an effect which can be observed in vitro and in vivo [<a href="#rid13">13-15</a>]. The effect in RA-sensitive NB4 cells in vivo is complex [<a href="#rid16">16</a>], with ATRA modulating expression of 169 genes in one study [<a href="#rid14">14</a>]. Although complete remission can be obtained with ATRA alone, most patients with APL will ultimately relapse without additional cytotoxic chemotherapy. The basis for development of ATRA resistance remains unclear, but this phenomenon suggests that additional genetic events might occur in APL cells that confer resistance. The use of <a class="drug drug_general" data-topicid="8977" href="/d/drug information/8977.html" rel="external">arsenic trioxide</a> has also been shown to induce remissions in APL, possibly by inducing the degradation of PML/RAR alpha [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/d/html/4505.html" rel="external">"Treatment of relapsed or refractory acute promyelocytic leukemia in adults"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">t(15;17) THE USUAL TRANSLOCATION IN APL</span><span class="headingEndMark"> — </span>The leukemic cells of approximately 92 percent of patients with acute promyelocytic leukemia (APL) have the balanced translocation t(15;17)(q24.1;q21.1) involving <em>RARA</em>, the retinoic acid receptor alpha gene on chromosome 17 and the <em>PML</em> (promyelocytic leukemia) gene on chromosome 15 [<a href="#rid5">5,7</a>]. An additional 5 percent of patients do not have the classic t(15;17), but have the <em>PML/RARA</em> fusion gene, due to insertions or other complex chromosomal rearrangements [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H4"><span class="h2">The PML gene</span><span class="headingEndMark"> — </span>The <em>PML</em> gene was first identified through its involvement with <em>RARA</em> in t(15;17) [<a href="#rid19">19,20</a>]. <em>PML</em> is expressed ubiquitously, and multiple alternative splice variants have been isolated. The normal function of the PML protein is not known, but overexpression of PML inhibits growth in cell lines, perhaps through the interferon gamma signaling pathway [<a href="#rid21">21</a>]. </p><p>The product of the <em>PML</em> gene is a nuclear protein that contains motifs suggestive of a role in control of RNA transcription, including two putative amino terminal DNA-binding domains and a potential dimerization domain. PML is normally expressed in myeloid progenitors, and has been shown to localize to a discrete subnuclear compartment of unknown function, referred to as the nuclear body (NB); the NB is also referred to as POD (PML oncogenic domain) or ND10 (nuclear domain 10) [<a href="#rid22">22,23</a>]. </p><p>In APL cells, NB integrity is disrupted and a microspeckled distribution of PML/RAR alpha is observed. NB disruption may contribute to disease pathogenesis and restoration of NB formation by <a class="drug drug_general" data-topicid="9262" href="/d/drug information/9262.html" rel="external">all-trans retinoic acid</a> (ATRA) or <a class="drug drug_general" data-topicid="8977" href="/d/drug information/8977.html" rel="external">arsenic trioxide</a> (ATO) correlates with their ability to induce remission of APL [<a href="#rid24">24</a>]. In a mouse model, mutations of PML that disrupted the NB increased the frequency of leukemia development, reduced the latency period, and impaired DNA damage responses [<a href="#rid25">25</a>]. </p><p>The following functional properties of the PML protein have been described [<a href="#rid26">26-28</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Localization of PML-associated proteins under physiological conditions</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Growth- and tumor-suppressor functions that are essential for certain apoptotic signals</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transcriptional co-activation with the tumor suppressor p53 (encoded by the <em>TP53 </em>gene)</p><p></p><p class="headingAnchor" id="H5"><span class="h2">The fusion genes of t(15;17)</span><span class="headingEndMark"> — </span>Two novel fusion genes are formed as a result of the t(15;17): a <em>PML/RARA</em> gene on the der(15) chromosome and an <em>RARA/PML</em> gene on the der(17) [<a href="#rid19">19,20</a>]. Whereas the <em>PML/RARA</em> fusion gene is found consistently in all cases of t(15;17), the reciprocal <em>RARA/PML</em> fusion can be detected in only 80 percent of cases [<a href="#rid29">29</a>] due, in some cases, to loss of the der(17) chromosome. Although this suggests that the RARA/PML fusion protein may not be essential in the pathogenesis of APL, its expression has been postulated to represent a potential second genetic event contributing to the leukemic phenotype.</p><p>The resulting fusion gene on der(15) encodes a fusion protein in which the DNA-binding and dimerization domains of PML are fused to the DNA-binding and C-terminal portions of RAR alpha, including the retinoid binding site. Breakpoints in <em>RARA</em> typically occur within intron 2, whereas breakpoints in <em>PML</em> are more heterogeneous, occurring within intron 3, intron 6, or exon 6, producing what has been called short, long, and variable forms [<a href="#rid30">30,31</a>]. The three different isoforms have somewhat different clinical characteristics; lack of sufficient numbers of patients with the less common variable form has made it difficult to determine whether the three isoforms have similar clinical outcomes [<a href="#rid30">30-32</a>].</p><p class="headingAnchor" id="H6"><span class="h3">Mechanism of action of PML/RARA</span><span class="headingEndMark"> — </span>The PML/RAR alpha protein functions as an aberrant retinoid receptor that possesses altered DNA binding and transcriptional regulatory properties [<a href="#rid33">33,34</a>]. PML/RAR alpha can heterodimerize with RXR and bind to retinoic acid (RA)-responsive elements in target genes. Expression of PML/RAR alpha blocks retinoic acid induced myeloid differentiation [<a href="#rid35">35</a>]. PML/RAR alpha can also block RAR alpha mediated transactivation in a dominant negative (DN) manner, as shown by experiments in which a DN mutation of <em>RARA</em> was introduced into a murine hematopoietic cell line; a block in differentiation along the neutrophil and monocytic lineages was observed and, instead, a switch to the development of mast cells and basophils occurred [<a href="#rid36">36</a>].</p><p>Experiments in transgenic mice demonstrated that expression of <em>PML/RARA</em> in immature myeloid cells resulted in the development of a leukemia with promyelocytic features, thereby demonstrating the leukemogenic potential of the fusion protein [<a href="#rid37">37</a>]. Expression of a <em>PML/RARA</em> variant that is unable to activate transcription in response to RA also leads to leukemia, but the leukemia does not differentiate in response to RA [<a href="#rid38">38</a>]. </p><p>The timing of <em>PML/RARA</em> expression during myeloid differentiation is a critical determinant in the development of leukemia. Comparison of the phenotypes in the transgenic mice that drive expression of <em>PML/RARA</em> under the control of various myeloid-specific promoters at specific stages of myeloid differentiation include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>In mice with the <em>PML/RARA</em> transgene expressed under the control of the human <em>MRP8</em> (myeloid related protein 8) promoter, which drives expression in early myeloid progenitors and in mature neutrophils and monocytes, neutrophil numbers were normal, but differentiation was impaired. Approximately 30 percent developed acute leukemia with a latency of three to nine months; remission of the leukemia could be induced by ATRA [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two groups generated transgenic mice expressing <em>PML/RARA</em> under the control of the <em>CTSG</em> (human cathepsin G) promoter, which drives expression in promonocytes and promyelocytes. These mice develop elevated numbers of immature myeloid cells in the bone marrow and peripheral blood. Approximately 10 to 30 percent develop leukemia with a latency of 12 to 14 months [<a href="#rid39">39,40</a>]. Treatment of these mice with ATRA caused apoptosis of myeloid precursors rather than differentiation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transgenic mice expressing <em>PML/RARA</em> under the control of the <em>ITGAM</em> (integrin subunit alpha M; CD11b) promoter have also been generated [<a href="#rid41">41</a>]. This promoter drives expression in later stages of myeloid differentiation. These mice do not develop leukemia and have normal numbers and maturation of myeloid cells. However, the ability of these mice to regenerate granulocytes following sublethal irradiation was impaired.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transgenic mice expressing <em>PML-RARA</em> in the setting of <em>PML</em> haploinsufficiency demonstrate a preferential expansion of PML/RAR alpha-expressing cells, suggesting that this transgene supports self-renewal [<a href="#rid42">42</a>]. This study showed that PML/RAR alpha can increase hematopoietic self-renewal without causing a myeloproliferative neoplasm in mice.</p><p></p><p>The relatively low frequency and long latency period for development of leukemia imply that genetic events in addition to the expression of <em>PML-RARA</em> are necessary in order for APL to occur [<a href="#rid43">43,44</a>]. </p><p>The precise way in which the fusion protein functions as an oncoprotein is incompletely understood. The two products of the t(15;17) translocation (ie, PML/RAR alpha and RAR alpha/PML) exhibit only subtle differences in function [<a href="#rid45">45</a>]. PML/RAR alpha shows reduced sensitivity to retinoic acid (RA) in terms of dissociation of N-CoR [<a href="#rid8">8</a>]. This could lead to persistent transcriptional repression, thereby preventing differentiation of promyelocytes. Pharmacologic concentrations of RA, as used in the treatment of APL, result in dissociation of N-CoR, presumably permitting differentiation of the leukemic cells [<a href="#rid8">8</a>].</p><p>The binding of the protein product of PML/RAR alpha is thought to repress gene transcription through epigenomic changes including histone deacetylation or methylation [<a href="#rid46">46,47</a>]. One theory holds that PML/RAR alpha creates homodimers that interact with histone methyltransferases, DNA methyltransferases, and histone deacetylases that act as corepressors [<a href="#rid47">47</a>]. Together, they bind and repress expression of differentiation genes thereby blocking differentiation at the promyelocyte stage (<a class="graphic graphic_figure graphicRef64089" href="/d/graphic/64089.html" rel="external">figure 1</a>).</p><p>A mechanism that includes the recruitment of a histone deacetylase may have therapeutic implications because in vitro studies have shown that resistance to <a class="drug drug_general" data-topicid="9262" href="/d/drug information/9262.html" rel="external">all-trans retinoic acid</a> can be overcome by the addition of a histone deacetylase inhibitor [<a href="#rid48">48,49</a>]. In addition, case reports and small trials have reported clinical responses to histone deacetylase inhibitors [<a href="#rid50">50,51</a>]. </p><p>PML/RAR alpha also may prolong the survival of the leukemic cells, perhaps in part by leading to downregulation of tumor necrosis factor-alpha (TNFa) receptors, thereby minimizing TNFa-induced apoptosis [<a href="#rid52">52</a>]. On the other hand, PML/RAR alpha in the presence of RA induces apoptosis in association with reduced levels of BCL2 which normally protects against apoptosis [<a href="#rid45">45</a>].</p><p>In support of this hypothesis are results obtained with mouse [<a href="#rid53">53</a>] and human [<a href="#rid54">54</a>] multipotent hematopoietic progenitor cells/stem cells (HPC/HSC) transfected in vitro with a retroviral vector containing <em>PML/RARA</em> cDNA. Expression of the PML/RAR alpha fusion protein in human cells dictated the APL phenotype through the following effects [<a href="#rid54">54</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Rapid induction of human HPC/HSC differentiation to the promyelocytic stage</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Maturation arrest at the promyelocytic stage, which was abolished by RA</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reprogramming of HPC commitment to preferential granulopoietic differentiation irrespective of the hematopoietic growth factor (HGF) stimulus</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Protection of HPC from apoptosis induced by HGF deprivation</p><p></p><p>Further mouse studies have demonstrated that expression of <em>PML/RARA</em> supports the immortalization of clonogenic myeloid progenitors also known as leukemia-initiating cells (LICs) [<a href="#rid47">47,55</a>]. The degradation of PML/RAR alpha by RA triggers the loss of these cells. The destruction of LICs, which are immune to the differentiation effects of RA, appears to be a key factor in the eradication of APL.</p><p class="headingAnchor" id="H7"><span class="h1">VARIANT TRANSLOCATIONS</span><span class="headingEndMark"> — </span>A number of variant translocations have been described in acute promyelocytic leukemia (APL), with t(11;17)(q23;q21.1), t(5;17)(q35;q21.1), and t(11;17)(q13;q21.1) being the most common.</p><p class="headingAnchor" id="H8"><span class="h2">PLZF/RARA and t(11;17)</span><span class="headingEndMark"> — </span>A variant translocation t(11;17)(q23;q21.1) has been described in approximately 1 percent of patients with APL [<a href="#rid18">18,56</a>]. In these tumors, the 3' end of the <em>RARA</em> gene is fused to the 5' end of a gene called <em>PLZF</em> (promyelocytic leukemia zinc finger), which encodes a protein containing nine zinc fingers, a motif frequently found in transcription factors. <em>PLZF</em> is expressed in myeloid but not lymphoid lineages, and its expression has been found to be downregulated during differentiation. Unlike PML, PLZF is not a component of nuclear bodies, but is localized in smaller, more numerous nuclear subdomains.</p><p>The <em>PLZF/RARA</em> fusion gene is predicted to encode a protein consisting of the amino terminal portion of PLZF, including several zinc fingers, and the same carboxy terminal portion of RAR alpha that is fused to PML in cells having t(15;17). The PLZF/RAR alpha fusion protein antagonizes the normal function of RAR alpha/RXR alpha heterodimers, suggesting that it behaves as a dominant negative mutant [<a href="#rid57">57</a>].</p><p>Although the number of cases studied is small, APL with t(11;17)(q23;q21.1) is usually <strong>refractory to therapy with retinoids</strong>, in contrast to the great majority of APL cases with the more common t(15;17) [<a href="#rid4">4,58</a>]. As noted above, <em>PML/RARA</em> in t(15;17) shows reduced sensitivity to retinoic acid (RA), but this can be overcome by pharmacological concentrations of RA. In contrast, pharmacological concentrations of RA do not induce dissociation of N-CoR from PLZF/RAR alpha, leading to persistent transcription repression and prevention of differentiation [<a href="#rid8">8,59</a>].</p><p class="headingAnchor" id="H9"><span class="h2">NPM/RARA and t(5;17)</span><span class="headingEndMark"> — </span>A rare (less than 0.5 percent) variant translocation in APL has been described, t(5;17)(q35;q21.1), in which the <em>NPM</em> (nucleophosmin) gene was fused to <em>RARA</em> [<a href="#rid18">18,60</a>]. NPM is a nucleolar phosphoprotein that is involved in ribosomal ribonucleoprotein processing and transport. <em>NPM</em> is also involved in the t(2;5)(p23;q35) in anaplastic large cell lymphoma, where it fuses to the <em>ALK</em> (anaplastic lymphoma kinase) gene. In addition, <em>NPM</em> has been found to fuse to the <em>MLF1</em> (myeloid leukemia factor 1) gene in t(3;5)(q25.1;q35) in AML. Patients with this translocation are <strong>responsive to ATRA therapy</strong> [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H10"><span class="h2">NuMA/RARA and t(11;17)</span><span class="headingEndMark"> — </span>In the translocation t(11;17)(q13;q21.1), the NuMA (nuclear matrix-mitotic apparatus protein) gene is fused with <em>RARA</em> [<a href="#rid7">7</a>]. Unlike t(11;17)(q23;q21.1), this variant appears <strong>responsive to ATRA</strong> [<a href="#rid61">61</a>].</p><p class="headingAnchor" id="H11"><span class="h2">STAT5B/RARA and interstitial chromosome 17 deletion</span><span class="headingEndMark"> — </span>A rare fusion between <em>STAT5B</em> (signal transducer and activator of transcription 5b) and <em>RARA</em> was found in a patient with an interstitial chromosome 17 deletion and an <strong>ATRA-resistant</strong> form of APL [<a href="#rid62">62-64</a>].</p><p class="headingAnchor" id="H175775309"><span class="h2">BCOR/RARA and t(X;17)(q11;q21.1)</span><span class="headingEndMark"> — </span>A case of APL demonstrating rectangular and round cytoplasmic inclusion bodies was found to have the translocation t(X;17)(q11;q21.1) resulting in a fusion between the <em>BCOR</em> (BCL6 corepressor) gene and <em>RARA</em> [<a href="#rid65">65</a>]. While this case was clinically responsive to ATRA, the patient had several episodes of relapse with standard chemotherapy plus ATRA.</p><p class="headingAnchor" id="H344450224"><span class="h1">FLT3 MUTATION</span><span class="headingEndMark"> — </span>FLT3 (FMS-like tyrosine kinase 3) is a transmembrane tyrosine kinase receptor that stimulates cell proliferation upon activation. Mutations in the <em>FLT3</em> gene producing internal tandem duplications (<em>FLT3</em>-ITD) and constitutive activation of the FLT3 tyrosine kinase are quite common in acute myeloid leukemia (AML), particularly in patients with normal karyotypes, and have been associated with poorer survival in children and in younger and older adults receiving intensive chemotherapy. The impact of <em>FLT3</em>-ITD mutations in patients with acute promyelocytic leukemia (APL) is more controversial.</p><p>In one study, <em>FLT3</em>-ITD mutations were identified in 35 of 171 patients (20 percent) with APL treated with all-trans retinoid acid (ATRA) plus anthracycline-based chemotherapy [<a href="#rid66">66</a>]. After a median follow-up of 38 months, <em>FLT3</em>-ITD positivity was associated with inferior overall survival at three years (62 versus 82 percent). While the prognostic impact of <em>FLT3</em>-ITD positivity was maintained on multivariate analysis, <em>FLT3</em>-ITD positivity was strongly associated with other features of severe disease, including high white blood cell counts at the time of presentation.</p><p>In another study, <em>FLT3</em>-ITD mutations were identified in 31 percent of 245 patients with APL treated with ATRA plus anthracycline-based chemotherapy with or without <a class="drug drug_general" data-topicid="8977" href="/d/drug information/8977.html" rel="external">arsenic trioxide</a> (ATO) consolidation [<a href="#rid67">67</a>]. <em>FLT3</em>-ITD positivity did not appear to impact remission rate, induction death rate, disease-free survival, or overall survival. ATO consolidation improved outcomes in patients with or without <em>FLT3</em>-ITD mutations.</p><p>These studies suggest that <em>FLT3</em>-ITD mutation is not an independent prognostic factor in patients with APL undergoing treatment with both ATO and ATRA-based therapy. <em>FLT3</em>-ITD mutation should not alter treatment decisions in this patient cohort.</p><p>Other genetic mutations may also contribute to disease pathogenesis. As an example, whole exome sequencing of 30 patients with newly diagnosed APL demonstrated <em>FLT3 </em>mutations and alterations in other genes (<em>STAG2, U2AF1, SMC1A, USP9X, IKZF1, LYN, MYCBP2,</em> and <em>PTPN11</em>) that have been implicated in other myeloid leukemias [<a href="#rid68">68</a>].</p><p class="headingAnchor" id="H2020802119"><span class="h1">RESISTANCE TO RETINOIC ACID TREATMENT</span><span class="headingEndMark"> — </span>Mutation analysis has identified several pathways that confer resistance to all-trans retinoid acid (ATRA) therapy in acute promyelocytic leukemia (APL). These genetic changes included acquired mutations in the ligand binding domain of <em>PML-RARA</em>, the acquisition of <em>FLT3</em>-ITD, and additional chromosome abnormalities [<a href="#rid69">69</a>]. A comprehensive mutational analysis of primary and relapsed APL also identified frequent mutations in the <em>PML</em> and <em>RARA</em> genes. </p><p>In addition, loss-of-function mutations were found in <em>ARID1B </em>and<em> ARID1A</em>, which encode key components of the SWI/SNF complex [<a href="#rid70">70</a>]. Increased expression of the pseudokinase Tribble 3 (TRIB3) is associated with APL progression and therapeutic resistance; increased TRIB3 expression suppresses the sumoylation, ubiquitylation, and degradation of PML-RAR alpha, which represses PML nuclear body assembly, p53-mediated senescence, and cell differentiation [<a href="#rid71">71</a>].</p><p>Management of APL that is resistant to <a class="drug drug_general" data-topicid="9262" href="/d/drug information/9262.html" rel="external">all-trans retinoic acid</a> treatment is discussed separately. (See  <a class="medical medical_review" href="/d/html/4505.html" rel="external">"Treatment of relapsed or refractory acute promyelocytic leukemia in adults"</a>.)</p><p class="headingAnchor" id="H358657"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Acute promyelocytic leukemia (APL) is a biologically and clinically distinct variant of acute myeloid leukemia that is characterized by a translocation involving the <em>RARA</em> (retinoic acid receptor [RAR] alpha) gene on chromosome 17.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>RAR alpha is a nuclear steroid/thyroid hormone receptor that is expressed primarily in hematopoietic cells. RAR alpha heterodimerizes with retinoid X receptor (RXR). These RAR alpha/RXR alpha heterodimers interact with the nuclear corepressor N-CoR, a ubiquitous nuclear protein that mediates transcriptional repression and presumably prevents terminal differentiation of promyelocytes. (See <a class="local">'Retinoic acid and the retinoic acid receptor'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The leukemic cells of more than 90 percent of patients with APL have the balanced translocation t(15;17)(q24.1;q21.1) involving the <em>RARA</em> gene on chromosome 17 and the <em>PML</em> (promyelocytic leukemia) gene on chromosome 15. An additional 5 percent do not have the classic t(15;17), but have the <em>PML/RARA</em> fusion gene, caused by insertions or other complex chromosomal rearrangements. (See <a class="local">'t(15;17) the usual translocation in APL'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The <em>PML</em> gene is expressed ubiquitously and its normal function is not known. Overexpression of <em>PML</em> inhibits growth in cell lines. (See <a class="local">'The PML gene'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two novel fusion genes are formed as a result of the t(15;17) (see <a class="local">'The fusion genes of t(15;17)'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A <em>PML/RARA</em> gene on the der(15) chromosome is found in all cases. The resulting rearrangement encodes a fusion protein in which the DNA-binding and dimerization domains of PML are fused to the DNA-binding and C-terminal portions of RAR alpha, including the retinoid binding site.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An <em>RARA/PML</em> gene on the der(17) can be detected in 80 percent of cases. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The PML/RAR alpha protein functions as an aberrant retinoid receptor expression that blocks retinoic acid induced myeloid differentiation. (See <a class="local">'Mechanism of action of PML/RARA'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A number of variant translocations have been described in APL that have therapeutic implications (see <a class="local">'Variant translocations'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>t(11;17)(q23;q21.1) is seen in approximately 1 percent of patients with APL and it results in the fusion of the <em>RARA</em> gene with the <em>PLZF</em> (promyelocytic leukemia zinc finger) gene, which is expressed in myeloid but not lymphoid lineages. APL with t(11;17)(q23;q11.12) is usually <strong>refractory to therapy with retinoids</strong>. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>t(5;17)(q35;q21.1) is seen in less than 0.5 percent of APL and results in the fusion of the <em>NPM</em> (nucleophosmin) gene to <em>RARA</em>. Patients with this translocation are <strong>responsive to ATRA therapy</strong>. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>t(11;17)(q13;q21.1) results in the fusion of the <em>NuMA</em> (nuclear matrix-mitotic apparatus protein) gene and <em>RARA</em>. This variant appears <strong>responsive to ATRA.</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A rare fusion between <em>STAT5B</em> and <em>RARA</em> was found in a patient with an interstitial chromosome 17 deletion and an <strong>ATRA-resistant</strong> form of APL.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Resistance of APL to ATRA treatment may be associated with mutations in <em>PML, RARA</em>, and other genes. (See <a class="local">'Resistance to retinoic acid treatment'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC Press, Lyon 2008.</li><li><a class="nounderline abstract_t">Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391.</a></li><li><a class="nounderline abstract_t">de Thé H, Chomienne C, Lanotte M, et al. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 1990; 347:558.</a></li><li><a class="nounderline abstract_t">Collins SJ. Acute promyelocytic leukemia: relieving repression induces remission. Blood 1998; 91:2631.</a></li><li><a class="nounderline abstract_t">Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999; 93:3167.</a></li><li><a class="nounderline abstract_t">Grimwade D. The pathogenesis of acute promyelocytic leukaemia: evaluation of the role of molecular diagnosis and monitoring in the management of the disease. Br J Haematol 1999; 106:591.</a></li><li><a class="nounderline abstract_t">Grignani F, Fagioli M, Alcalay M, et al. Acute promyelocytic leukemia: from genetics to treatment. Blood 1994; 83:10.</a></li><li><a class="nounderline abstract_t">Guidez F, Ivins S, Zhu J, et al. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood 1998; 91:2634.</a></li><li><a class="nounderline abstract_t">Mueller BU, Pabst T, Fos J, et al. ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression. Blood 2006; 107:3330.</a></li><li><a class="nounderline abstract_t">Breitman TR, Collins SJ, Keene BR. Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid. Blood 1981; 57:1000.</a></li><li><a class="nounderline abstract_t">Robertson KA, Emami B, Mueller L, Collins SJ. Multiple members of the retinoic acid receptor family are capable of mediating the granulocytic differentiation of HL-60 cells. Mol Cell Biol 1992; 12:3743.</a></li><li><a class="nounderline abstract_t">Gratas C, Menot ML, Dresch C, Chomienne C. Retinoid acid supports granulocytic but not erythroid differentiation of myeloid progenitors in normal bone marrow cells. Leukemia 1993; 7:1156.</a></li><li><a class="nounderline abstract_t">Warrell RP Jr, de Thé H, Wang ZY, Degos L. Acute promyelocytic leukemia. N Engl J Med 1993; 329:177.</a></li><li><a class="nounderline abstract_t">Liu TX, Zhang JW, Tao J, et al. Gene expression networks underlying retinoic acid-induced differentiation of acute promyelocytic leukemia cells. Blood 2000; 96:1496.</a></li><li><a class="nounderline abstract_t">Cassinat B, Chevret S, Zassadowski F, et al. In vitro all-trans retinoic acid sensitivity of acute promyelocytic leukemia blasts: a novel indicator of poor patient outcome. Blood 2001; 98:2862.</a></li><li><a class="nounderline abstract_t">Altucci L, Rossin A, Raffelsberger W, et al. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat Med 2001; 7:680.</a></li><li><a class="nounderline abstract_t">Nasr R, Lallemand-Breitenbach V, Zhu J, et al. Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure. Clin Cancer Res 2009; 15:6321.</a></li><li><a class="nounderline abstract_t">Grimwade D, Biondi A, Mozziconacci MJ, et al. Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Groupe Français de Cytogénétique Hématologique, Groupe de Français d'Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action "Molecular Cytogenetic Diagnosis in Haematological Malignancies". Blood 2000; 96:1297.</a></li><li><a class="nounderline abstract_t">de Thé H, Lavau C, Marchio A, et al. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991; 66:675.</a></li><li><a class="nounderline abstract_t">Kakizuka A, Miller WH Jr, Umesono K, et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 1991; 66:663.</a></li><li><a class="nounderline abstract_t">Choi YH, Bernardi R, Pandolfi PP, Benveniste EN. The promyelocytic leukemia protein functions as a negative regulator of IFN-gamma signaling. Proc Natl Acad Sci U S A 2006; 103:18715.</a></li><li><a class="nounderline abstract_t">Weis K, Rambaud S, Lavau C, et al. Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells. Cell 1994; 76:345.</a></li><li><a class="nounderline abstract_t">Dyck JA, Maul GG, Miller WH Jr, et al. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell 1994; 76:333.</a></li><li><a class="nounderline abstract_t">Zhu J, Koken MH, Quignon F, et al. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci U S A 1997; 94:3978.</a></li><li><a class="nounderline abstract_t">Voisset E, Moravcsik E, Stratford EW, et al. Pml nuclear body disruption cooperates in APL pathogenesis and impairs DNA damage repair pathways in mice. Blood 2018; 131:636.</a></li><li><a class="nounderline abstract_t">Maul GG, Negorev D, Bell P, Ishov AM. Review: properties and assembly mechanisms of ND10, PML bodies, or PODs. J Struct Biol 2000; 129:278.</a></li><li><a class="nounderline abstract_t">Guo A, Salomoni P, Luo J, et al. The function of PML in p53-dependent apoptosis. Nat Cell Biol 2000; 2:730.</a></li><li><a class="nounderline abstract_t">Zhong S, Salomoni P, Ronchetti S, et al. Promyelocytic leukemia protein (PML) and Daxx participate in a novel nuclear pathway for apoptosis. J Exp Med 2000; 191:631.</a></li><li><a class="nounderline abstract_t">Goddard AD, Borrow J, Freemont PS, Solomon E. Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. Science 1991; 254:1371.</a></li><li><a class="nounderline abstract_t">Gallagher RE, Willman CL, Slack JL, et al. Association of PML-RAR alpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study. Blood 1997; 90:1656.</a></li><li><a class="nounderline abstract_t">Slack JL, Willman CL, Andersen JW, et al. Molecular analysis and clinical outcome of adult APL patients with the type V PML-RARalpha isoform: results from intergroup protocol 0129. Blood 2000; 95:398.</a></li><li><a class="nounderline abstract_t">González M, Barragán E, Bolufer P, et al. Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RAR alpha isoforms: a study of the PETHEMA group. Br J Haematol 2001; 114:99.</a></li><li><a class="nounderline abstract_t">Perez A, Kastner P, Sethi S, et al. PMLRAR homodimers: distinct DNA binding properties and heteromeric interactions with RXR. EMBO J 1993; 12:3171.</a></li><li><a class="nounderline abstract_t">Côté S, Zhou D, Bianchini A, et al. Altered ligand binding and transcriptional regulation by mutations in the PML/RARalpha ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia. Blood 2000; 96:3200.</a></li><li><a class="nounderline abstract_t">Grignani F, Ferrucci PF, Testa U, et al. The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 1993; 74:423.</a></li><li><a class="nounderline abstract_t">Tsai S, Bartelmez S, Heyman R, et al. A mutated retinoic acid receptor-alpha exhibiting dominant-negative activity alters the lineage development of a multipotent hematopoietic cell line. Genes Dev 1992; 6:2258.</a></li><li><a class="nounderline abstract_t">Brown D, Kogan S, Lagasse E, et al. A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci U S A 1997; 94:2551.</a></li><li><a class="nounderline abstract_t">Kogan SC, Hong SH, Shultz DB, et al. Leukemia initiated by PMLRARalpha: the PML domain plays a critical role while retinoic acid-mediated transactivation is dispensable. Blood 2000; 95:1541.</a></li><li><a class="nounderline abstract_t">Grisolano JL, Wesselschmidt RL, Pelicci PG, Ley TJ. Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences. Blood 1997; 89:376.</a></li><li><a class="nounderline abstract_t">He LZ, Tribioli C, Rivi R, et al. Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. Proc Natl Acad Sci U S A 1997; 94:5302.</a></li><li><a class="nounderline abstract_t">Early E, Moore MA, Kakizuka A, et al. Transgenic expression of PML/RARalpha impairs myelopoiesis. Proc Natl Acad Sci U S A 1996; 93:7900.</a></li><li><a class="nounderline abstract_t">Welch JS, Yuan W, Ley TJ. PML-RARA can increase hematopoietic self-renewal without causing a myeloproliferative disease in mice. J Clin Invest 2011; 121:1636.</a></li><li><a class="nounderline abstract_t">Kogan SC, Brown DE, Shultz DB, et al. BCL-2 cooperates with promyelocytic leukemia retinoic acid receptor alpha chimeric protein (PMLRARalpha) to block neutrophil differentiation and initiate acute leukemia. J Exp Med 2001; 193:531.</a></li><li><a class="nounderline abstract_t">Le Beau MM, Bitts S, Davis EM, Kogan SC. Recurring chromosomal abnormalities in leukemia in PML-RARA transgenic mice parallel human acute promyelocytic leukemia. Blood 2002; 99:2985.</a></li><li><a class="nounderline abstract_t">Slack JL, Yu M. Constitutive expression of the promyelocytic leukemia-associated oncogene PML-RARalpha in TF1 cells: isoform-specific and retinoic acid-dependent effects on growth, bcl-2 expression, and apoptosis. Blood 1998; 91:3347.</a></li><li><a class="nounderline abstract_t">Hoemme C, Peerzada A, Behre G, et al. Chromatin modifications induced by PML-RARalpha repress critical targets in leukemogenesis as analyzed by ChIP-Chip. Blood 2008; 111:2887.</a></li><li><a class="nounderline abstract_t">Licht JD. Acute promyelocytic leukemia--weapons of mass differentiation. N Engl J Med 2009; 360:928.</a></li><li><a class="nounderline abstract_t">Lin RJ, Nagy L, Inoue S, et al. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998; 391:811.</a></li><li><a class="nounderline abstract_t">Grignani F, De Matteis S, Nervi C, et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 1998; 391:815.</a></li><li><a class="nounderline abstract_t">Warrell RP Jr, He LZ, Richon V, et al. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 1998; 90:1621.</a></li><li><a class="nounderline abstract_t">Bug G, Ritter M, Wassmann B, et al. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer 2005; 104:2717.</a></li><li><a class="nounderline abstract_t">Testa U, Grignani F, Samoggia P, et al. The PML/RARalpha fusion protein inhibits tumor necrosis factor-alpha-induced apoptosis in U937 cells and acute promyelocytic leukemia blasts. J Clin Invest 1998; 101:2278.</a></li><li><a class="nounderline abstract_t">Minucci S, Monestiroli S, Giavara S, et al. PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitors. Blood 2002; 100:2989.</a></li><li><a class="nounderline abstract_t">Grignani F, Valtieri M, Gabbianelli M, et al. PML/RAR alpha fusion protein expression in normal human hematopoietic progenitors dictates myeloid commitment and the promyelocytic phenotype. Blood 2000; 96:1531.</a></li><li><a class="nounderline abstract_t">Nasr R, Guillemin MC, Ferhi O, et al. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med 2008; 14:1333.</a></li><li><a class="nounderline abstract_t">Chen Z, Brand NJ, Chen A, et al. Fusion between a novel Krüppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. EMBO J 1993; 12:1161.</a></li><li><a class="nounderline abstract_t">Chen Z, Guidez F, Rousselot P, et al. PLZF-RAR alpha fusion proteins generated from the variant t(11;17)(q23;q21) translocation in acute promyelocytic leukemia inhibit ligand-dependent transactivation of wild-type retinoic acid receptors. Proc Natl Acad Sci U S A 1994; 91:1178.</a></li><li><a class="nounderline abstract_t">Guidez F, Huang W, Tong JH, et al. Poor response to all-trans retinoic acid therapy in a t(11;17) PLZF/RAR alpha patient. Leukemia 1994; 8:312.</a></li><li><a class="nounderline abstract_t">Licht JD, Chomienne C, Goy A, et al. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood 1995; 85:1083.</a></li><li><a class="nounderline abstract_t">Redner RL, Rush EA, Faas S, et al. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood 1996; 87:882.</a></li><li><a class="nounderline abstract_t">Wells RA, Hummel JL, De Koven A, et al. A new variant translocation in acute promyelocytic leukaemia: molecular characterization and clinical correlation. Leukemia 1996; 10:735.</a></li><li><a class="nounderline abstract_t">Arnould C, Philippe C, Bourdon V, et al. The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia. Hum Mol Genet 1999; 8:1741.</a></li><li><a class="nounderline abstract_t">Dong S, Tweardy DJ. Interactions of STAT5b-RARalpha, a novel acute promyelocytic leukemia fusion protein, with retinoic acid receptor and STAT3 signaling pathways. Blood 2002; 99:2637.</a></li><li><a class="nounderline abstract_t">Collins SJ. Acute promyelocytic leukemia: STATs, HATs, and HDACs. Blood 2002; 99:2635.</a></li><li><a class="nounderline abstract_t">Yamamoto Y, Tsuzuki S, Tsuzuki M, et al. BCOR as a novel fusion partner of retinoic acid receptor alpha in a t(X;17)(p11;q12) variant of acute promyelocytic leukemia. Blood 2010; 116:4274.</a></li><li><a class="nounderline abstract_t">Lucena-Araujo AR, Kim HT, Jacomo RH, et al. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study. Ann Hematol 2014; 93:2001.</a></li><li><a class="nounderline abstract_t">Poiré X, Moser BK, Gallagher RE, et al. Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype. Leuk Lymphoma 2014; 55:1523.</a></li><li><a class="nounderline abstract_t">Ibáñez M, Carbonell-Caballero J, García-Alonso L, et al. The Mutational Landscape of Acute Promyelocytic Leukemia Reveals an Interacting Network of Co-Occurrences and Recurrent Mutations. PLoS One 2016; 11:e0148346.</a></li><li><a class="nounderline abstract_t">Gallagher RE, Moser BK, Racevskis J, et al. Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia. Blood 2012; 120:2098.</a></li><li><a class="nounderline abstract_t">Madan V, Shyamsunder P, Han L, et al. Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. Leukemia 2016; 30:1672.</a></li><li><a class="nounderline abstract_t">Li K, Wang F, Cao WB, et al. TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RARα and Inhibition of p53-Mediated Senescence. Cancer Cell 2017; 31:697.</a></li></ol></div><div id="topicVersionRevision">Topic 4523 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC Press, Lyon 2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27069254" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2170850" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9531569" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Acute promyelocytic leukemia: relieving repression induces remission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10233871" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10468848" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The pathogenesis of acute promyelocytic leukaemia: evaluation of the role of molecular diagnosis and monitoring in the management of the disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8274729" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Acute promyelocytic leukemia: from genetics to treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9531570" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16352814" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6939451" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1324405" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Multiple members of the retinoic acid receptor family are capable of mediating the granulocytic differentiation of HL-60 cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8350615" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Retinoid acid supports granulocytic but not erythroid differentiation of myeloid progenitors in normal bone marrow cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8515790" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Acute promyelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10942397" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Gene expression networks underlying retinoic acid-induced differentiation of acute promyelocytic leukemia cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11675363" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : In vitro all-trans retinoic acid sensitivity of acute promyelocytic leukemia blasts: a novel indicator of poor patient outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11385504" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19808868" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10942371" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Groupe Français de Cytogénétique Hématologique, Groupe de Français d'Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action "Molecular Cytogenetic Diagnosis in Haematological Malignancies".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1652369" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1652368" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17121994" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The promyelocytic leukemia protein functions as a negative regulator of IFN-gamma signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8293468" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8293467" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9108090" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29191918" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Pml nuclear body disruption cooperates in APL pathogenesis and impairs DNA damage repair pathways in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10806078" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Review: properties and assembly mechanisms of ND10, PML bodies, or PODs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11025664" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The function of PML in p53-dependent apoptosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10684855" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Promyelocytic leukemia protein (PML) and Daxx participate in a novel nuclear pathway for apoptosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1720570" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9269786" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Association of PML-RAR alpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10627441" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Molecular analysis and clinical outcome of adult APL patients with the type V PML-RARalpha isoform: results from intergroup protocol 0129.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11472351" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RAR alpha isoforms: a study of the PETHEMA group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8393784" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : PMLRAR homodimers: distinct DNA binding properties and heteromeric interactions with RXR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11050004" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Altered ligand binding and transcriptional regulation by mutations in the PML/RARalpha ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8394219" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1334022" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A mutated retinoic acid receptor-alpha exhibiting dominant-negative activity alters the lineage development of a multipotent hematopoietic cell line.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9122233" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A PMLRARalpha transgene initiates murine acute promyelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10688806" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Leukemia initiated by PMLRARalpha: the PML domain plays a critical role while retinoic acid-mediated transactivation is dispensable.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9002938" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9144232" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8755574" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Transgenic expression of PML/RARalpha impairs myelopoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21364283" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : PML-RARA can increase hematopoietic self-renewal without causing a myeloproliferative disease in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11181704" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : BCL-2 cooperates with promyelocytic leukemia retinoic acid receptor alpha chimeric protein (PMLRARalpha) to block neutrophil differentiation and initiate acute leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11929790" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Recurring chromosomal abnormalities in leukemia in PML-RARA transgenic mice parallel human acute promyelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9558392" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Constitutive expression of the promyelocytic leukemia-associated oncogene PML-RARalpha in TF1 cells: isoform-specific and retinoic acid-dependent effects on growth, bcl-2 expression, and apoptosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18024792" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Chromatin modifications induced by PML-RARalpha repress critical targets in leukemogenesis as analyzed by ChIP-Chip.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19246367" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Acute promyelocytic leukemia--weapons of mass differentiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9486654" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Role of the histone deacetylase complex in acute promyelocytic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9486655" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9811311" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16294345" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9593784" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The PML/RARalpha fusion protein inhibits tumor necrosis factor-alpha-induced apoptosis in U937 cells and acute promyelocytic leukemia blasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12351412" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10942402" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : PML/RAR alpha fusion protein expression in normal human hematopoietic progenitors dictates myeloid commitment and the promyelocytic phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19029980" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8384553" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Fusion between a novel Krüppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8302850" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : PLZF-RAR alpha fusion proteins generated from the variant t(11;17)(q23;q21) translocation in acute promyelocytic leukemia inhibit ligand-dependent transactivation of wild-type retinoic acid receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8309256" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Poor response to all-trans retinoic acid therapy in a t(11;17) PLZF/RAR alpha patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7849296" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8562957" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8618456" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A new variant translocation in acute promyelocytic leukaemia: molecular characterization and clinical correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10441338" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11929748" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Interactions of STAT5b-RARalpha, a novel acute promyelocytic leukemia fusion protein, with retinoic acid receptor and STAT3 signaling pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Acute promyelocytic leukemia: STATs, HATs, and HDACs</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20807888" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : BCOR as a novel fusion partner of retinoic acid receptor alpha in a t(X;17)(p11;q12) variant of acute promyelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24981688" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24160850" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26886259" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The Mutational Landscape of Acute Promyelocytic Leukemia Reveals an Interacting Network of Co-Occurrences and Recurrent Mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22734072" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Treatment-influenced associations of PML-RARαmutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27063598" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28486108" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RARαand Inhibition of p53-Mediated Senescence.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
